Optorhythm
Optogenetic therapy for the Treatment of Atrial Fibrillation with an Implantable Optic
Company Overview
Snapshot
Founded in August 2024 by Yaki Eidelstein, Optorhythm operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II. In September 2024, Optorhythm received pre-seed funding from NGT HealthCare II.
Business overview
Optorhythm is developing a novel light-based method for controlling heart rhythms, specifically targeting Atrial Fibrillation (AF). The company's core technology integrates optogenetic gene therapy with an implantable micro-LED array to create an "Optic Defibrillator." This device aims to stop chaotic atrial contractions through targeted light pulses, offering a real-time, repeatable, and non-destructive alternative to traditional electric shocks. Optorhythm serves the healthcare industry, focusing on medical devices and medical treatment & therapeutics within the Health Tech & Life Sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Optorhythm's primary focus?
- Optorhythm is developing a novel light-based method for controlling heart rhythms, specifically for the treatment of Atrial Fibrillation (AF).
- Who founded Optorhythm?
- Optorhythm was founded by Yaki Eidelstein, who serves as Co-founder & CEO.
- When was Optorhythm founded?
- Optorhythm was founded in August 2024.
- What is Optorhythm's core technology?
- Optorhythm's core technology integrates optogenetic gene therapy with an implantable micro-LED array to create an Optic Defibrillator, designed to stop chaotic atrial contractions through targeted light pulses.
- Which investor participated in Optorhythm's funding round?
- In September 2024, Optorhythm received pre-seed funding from NGT HealthCare II.